- Home
- ATOS vs TCRX Comparison
ATOS vs TCRX Comparison
Compare ATOS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- TCRX
- Stock Information
- Founded
- ATOS 2009
- TCRX 2018
- Country
- ATOS United States
- TCRX United States
- Employees
- ATOS N/A
- TCRX N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- TCRX Health Care
- Exchange
- ATOS Nasdaq
- TCRX Nasdaq
- Market Cap
- ATOS 107.2M
- TCRX 91.7M
- IPO Year
- ATOS 2012
- TCRX 2021
- Fundamental
- Price
- ATOS $0.84
- TCRX $1.76
- Analyst Decision
- ATOS Strong Buy
- TCRX Strong Buy
- Analyst Count
- ATOS 3
- TCRX 5
- Target Price
- ATOS $6.17
- TCRX $9.40
- AVG Volume (30 Days)
- ATOS 473.0K
- TCRX 212.0K
- Earning Date
- ATOS 11-11-2025
- TCRX 11-11-2025
- Dividend Yield
- ATOS N/A
- TCRX N/A
- EPS Growth
- ATOS N/A
- TCRX N/A
- EPS
- ATOS N/A
- TCRX N/A
- Revenue
- ATOS N/A
- TCRX $6,961,000.00
- Revenue This Year
- ATOS N/A
- TCRX $255.18
- Revenue Next Year
- ATOS N/A
- TCRX N/A
- P/E Ratio
- ATOS N/A
- TCRX N/A
- Revenue Growth
- ATOS N/A
- TCRX N/A
- 52 Week Low
- ATOS $0.55
- TCRX $1.02
- 52 Week High
- ATOS $1.66
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- ATOS 60.84
- TCRX 46.01
- Support Level
- ATOS $0.81
- TCRX $1.73
- Resistance Level
- ATOS $0.80
- TCRX $1.96
- Average True Range (ATR)
- ATOS 0.03
- TCRX 0.11
- MACD
- ATOS 0.01
- TCRX -0.01
- Stochastic Oscillator
- ATOS 92.67
- TCRX 16.67
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.